Moderna Inc
MRNA
Company Profile
Business description
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Contact
200 Technology Square
CambridgeMA02139
USAT: +1 617 714-6500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
5,600
Moderna Inc News & Analysis
stocks
3 vaccine stocks that could get a boost on China outbreaks
Fresh pandemic fears may stoke demand for these vaccine makers.
stocks
COVID-19 vaccine booster plans match our expectations
We don’t expect any changes to our fair value estimates or moat ratings for the mRNA manufacturers.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,633.10 | 66.10 | 0.77% |
| CAC 40 | 7,255.01 | 41.69 | 0.58% |
| DAX 40 | 19,322.59 | 176.42 | 0.92% |
| Dow JONES (US) | 44,296.51 | 426.16 | 0.97% |
| FTSE 100 | 8,262.08 | 112.81 | 1.38% |
| HKSE | 19,229.97 | 371.14 | -1.89% |
| NASDAQ | 19,003.65 | 31.23 | 0.16% |
| Nikkei 225 | 38,283.85 | 257.68 | 0.68% |
| NZX 50 Index | 13,041.90 | 276.66 | 2.17% |
| S&P 500 | 5,969.34 | 20.63 | 0.35% |
| S&P/ASX 200 | 8,393.80 | 70.80 | 0.85% |
| SSE Composite Index | 3,267.19 | 103.21 | -3.06% |